AstraZeneca takes COVID-19 vaccine to China with BioKangtai deal for 200M-dose capacity by 2021 Groups call on Congress to OK $50B in relief funds — plus some strings attached — to help providers In the face of COVID-19, cell and gene therapy space shows ‘remarkable resilience:’ report House Dems launch probe into Kodak's unexpected $765M drug manufacturing loan from the feds There needs to be a policy "reset" for physicians post-COVID, healthcare leaders say Biopharma roundup: NIH teams Gilead, Merck KGaA meds in new trial; Radiology collab aims AI at COVID NIH launches imaging AI collaboration for COVID-19 and beyond Employers are tweaking health benefits amid COVID-19. Will workers take advantage of it? Trump to issue ‘Buy American’ executive order for essential drugs: reports Amid COVID deal spree, Catalent plots Argentina manufacturing scale-up Featured Story | By Angus Liu AstraZeneca has reached a licensing deal with Chinese firm BioKangtai to help provide its adenovirus-based COVID-19 vaccine candidate to China, AZ's second-largest market. The local partner will make sure to have enough capacity to make at least 100 million doses of the shot by 2020. read more |
| |
|---|
|
| | New vaccines will save lives. Who will save the vaccines? The world’s pharmaceutical cold chains do not at this time have the equipment and scale to safely and compliantly deliver a temperature-sensitive COVID-19 vaccine. Click to learn more about emerging trends in vaccine logistics and distribution.
*Republished with permission, this article first appeared on UPS’s thought leadership blog, Longitudes. |
Top Stories By Robert King Several advocacy groups are pressing Congress to allocate more COVID-19 relief funding for providers, but with a twist to give more money to providers that participate in alternative payment models. read more By Amirah Al Idrus In the early days of COVID-19, the Alliance for Regenerative Medicine was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space. Now, the numbers are in—and they’re better than ever. In the first half of 2020, the sector raised $10.7 billion, more than the total it raised in 2019. read more By Angus Liu The Trump administration’s surprising $765 million deal to help former photography giant Kodak to start making drug ingredients has yet to be finalized, and it’s already attracted plenty of controversy. First, insider trading allegations from the U.S. Senate—and now, an investigation by House Democrats. read more By Heather Landi The COVID-19 pandemic offers an opportunity for a practice and policy "reset" to help permanently reduce administrative headaches for physicians, according to two healthcare leaders. Here is why two doctors believe there are important policy lessons to be learned from the current pandemic. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Gilead's antiviral remdesivir and Merck KGaA's interferon-based med Rebif are teaming up against coronavirus in a new NIH trial. The German drugmaker's CFO has some thoughts about vaccine timing. A radiology collab aims to use AI and imaging to quickly diagnose cases. And researchers in South Korea confirmed what experts already believed: Asymptomatic people do spread COVID-19. read more By Conor Hale The NIH is turning to AI and medical imaging to not only detect cases of COVID-19 earlier, but to help personalize treatments for the spreading disease. read more By Paige Minemyer Employers are making adjustments to their health benefits in the wake of COVID-19, but workers may not take the time to consider these new options, a survey from Fidelity shows. read more By Eric Sagonowsky Shortly after issuing four drug pricing executive orders—including one that generated significant pushback from the pharmaceutical industry—President Donald Trump is set to sign another centered on U.S. production for drugs and medical supplies, according to reports. Pharma's not likely to be any happier this time. read more By Fraiser Kansteiner Catalent has made waves of late with a series of high-profile coronavirus vaccine deals. Now, the New Jersey-based CDMO is plotting an upgrade to its plant in Buenos Aires, where it aims to churn out high-potency treatments for diseases like cancer, to the tune of 10 million additional doses per year. read more |
